Merkel cell carcinoma (MCC) is an aggressive skin malignancy with two distinct etiologies.
The first, which accounts for the highest proportion, is caused by Merkel cell polyomavirus …

Abstract Retifanlimab (retifanlimab-dlwr; ZYNYZTM) is a programmed cell death 1 receptor-
blocking antibody that is being developed by Incyte Corporation for the treatment of solid …

Background Merkel cell carcinoma (MCC) is an immunogenic but aggressive skin cancer.
Even after complete resection and radiation, relapse rates are high. PD-1 and PD-L1 …

Skin cancer encompasses a range of cutaneous malignancies, with non-melanoma skin
cancers (NMSCs) being the most common neoplasm worldwide. Skin exposure is the …

The prognosis of patients with advanced high-grade (G3) digestive neuroendocrine
neoplasms (NENs) is rather poor. The addition of immune checkpoint inhibition to platinum …

Abstract Background Metastatic Merkel cell carcinoma (mMCC) is highly responsive to
immune checkpoint inhibitors (ICIs); however, durability of response after treatment …

Merkel cell carcinoma (MCC) is a rare cancer of the skin characterized by a neuroendocrine
phenotype and an aggressive clinical behavior. It frequently originates in sun-exposed body …

Merkel cell carcinoma (MCC) is an uncommon primary cutaneous neuroendocrine
carcinoma associated with an adverse prognosis. In recent years, our understanding of …

Simple Summary Merkel cell carcinoma is a very rare and highly aggressive
neuroendocrine carcinoma originating from the skin. Exceptionally it presents with a nodal …

Background Immune checkpoint inhibitor treatment of patients with metastatic Merkel cell
carcinoma (mMCC) has shown high response rates, ranging from 33% to 73%. The ideal …